Genetic evaluation of mesenchymal stem cells

Cornélio, Deborah Afonso; Medeiros, Sílvia Regina Batistuzzo de

doi:10.1016/j.bjhh.2014.05.014

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in a study by Tarte et al, aneuploidy without risk of transformation occurring in a long-term culture of clinical grade MSCs was most likely donor dependent (3 out of 5 aberrations were derived from the same donor) [118]. Thus, donor screening and monitoring of the long-term expansion and integrity of the cells are a requirement [119].…”

Section: Risk Of Modulating the Action Of Immune Cells And The Dilmentioning

confidence: 99%

Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System

Guerrouahen

Sidahmed

Sulaiti

et al. 2019

Stem Cells International

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs), formerly known as mesenchymal stem cells, are nonhematopoietic multipotent cells and are emerging worldwide as the most clinically used and promising source for allogeneic cell therapy. MSCs, initially obtained from bone marrow, can be derived from several other tissues, such as adipose tissue, placenta, and umbilical cord. Diversity in tissue sourcing and manufacturing procedures has significant effects on MSC products. However, in 2006, a minimal set of standard criteria has been issued by the International Society of Cellular Therapy for defining derived MSCs. These include adherence to plastic in conventional culture conditions, particular phenotype, and multilineage differentiation capacity in vitro. Moreover, MSCs have trophic capabilities, a high in vitro self-renewal ability, and immunomodulatory characteristics. Thus, immunosuppressive treatment with MSCs has been proposed as a potential therapeutic alternative for conditions in which the immune system cells influence outcomes, such as inflammatory and autoimmune diseases. The precise mechanism by which MSCs affect functions of most immune effector cells is not completely understood but involves direct contact with immune cells, soluble mediators, and local microenvironmental factors. Recently, it has been shown that their homeostatic resting state requires activation, which can be achieved in vitro with various cytokines, including interferon-γ. In the present review, we focus on the suppressive effect that MSCs exert on the immune system and highlight the significance of in vitro preconditioning and its use in preclinical studies. We discuss the clinical aspects of using MSCs as an immunomodulatory treatment. Finally, we comment on the risk of interfering with the immune system in regard to cancer formation and development.

show abstract

Section: Risk Of Modulating the Action Of Immune Cells And The Dilmentioning

confidence: 99%

Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System

Guerrouahen

Sidahmed

Sulaiti

et al. 2019

Stem Cells International

View full text Add to dashboard Cite

show abstract

Novel approaches using mesenchymal stem cells for curing peripheral nerve injuries

et al. 2019

View full text Add to dashboard Cite

^{Tissue Engineering Strategies to Improve Osteogenesis in the Juvenile Swine Alveolar Cleft Model}

CaballeroMontserrat

JonesDonna

ShanZhengyuan

et al. 2017

Tissue Engineering Part C: Methods

View full text Add to dashboard Cite

Alveolar (gumline) clefts are the most common congenital bone defect in humans, affecting 1 in 700 live births. Treatment to repair these bony defects relies on autologous, cancellous bone transfer from the iliac crest. This harvest requires a second surgical site with increased surgical time associated with potential complications, while providing only limited cancellous bone. Improvements in treatment protocols that avoid these limitations would be beneficial to patients with clefts and other craniofacial bone defects. There have been steady advances in tissue-engineered (TE) solutions for long-bone defects and adult patients, but advances for the pediatric craniofacial skeleton have been slower to emerge. This study utilizes a previously established juvenile swine model with a surgically created, critical size alveolar defect to test the efficacy of umbilical cord (UC) mesenchymal stem cells (MSCs) treatments on nano-microfiber scaffolds. At 1 month after implanting our TE construct, mineralized tissue in the surgical gap was quantified through computed tomography (CT), and histology, and excised tissue was subjected to mechanical testing. Both undifferentiated and predifferentiated (toward an osteogenic lineage) UC MSCs generated bone within the cleft on a scale comparable to iliac crest cancellous bone, as evidenced by histology and CT scans. All of the pigs treated with scaffold/stem cell combinations had mineralized tissue within the defect, although without filling the entire defect. Several of the experimental animals exhibited poor and/or asymmetric maxillary growth 1 month after the initial surgery, especially if the surgical defect was located on the smaller side of an already asymmetric pig. Our results demonstrate that tissue engineering approaches using UC MSCs are a promising alternative for repair of the alveolar cleft. Data in the pig model demonstrate that implanted scaffolds are at least as good as the current gold standard treatment based on harvesting cancellous bone from the iliac crest, regardless of whether the cells seeded on the scaffold are precommitted to an osteogenic fate.

show abstract

Genetic evaluation of mesenchymal stem cells

Cited by 4 publications

References 23 publications

Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System

Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System

Novel approaches using mesenchymal stem cells for curing peripheral nerve injuries

^{Tissue Engineering Strategies to Improve Osteogenesis in the Juvenile Swine Alveolar Cleft Model}

Contact Info

Product

Resources

About